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 2 
Abstract 3 
Aims 4 
In this randomized controlled trial (RCT), we aimed to compare post-operative bone 5 
remodeling and bone turnover over 2 years following total hip arthroplasty using the short, 6 
proximally-coated Tri-Lock ‘Bone-Preserving Stem’ versus a conventional, fully-coated 7 
Corail prosthesis. 8 
Methods 9 
Forty-six participants received the Tri-Lock prosthesis and 40 received the Corail. At 10 
baseline, both groups had similar demographics, proximal femoral bone mineral density 11 
(BMD), bone turnover markers, radiographic canal flare index, and patient-reported 12 
outcome measure scores. Outcomes were measured at week 26, 52, and 104. 13 
Results 14 
Loss in periprosthetic bone, measured by high sensitivity Dual-energy X-ray 15 
Absorptiometry Region Free Analysis (DXA-RFA) was identified at the calcar and 16 
proximal lateral femur in both prosthesis groups (p<0.05). However, the conventional 17 
prosthesis demonstrated a smaller reduction in BMD versus the bone-preserving prosthesis 18 
(p<0.001). This effect was most prominent in the region of the femoral calcar and greater 19 
trochanter. A small gain in BMD was also identified in some areas that was greater with 20 
the conventional versus the bone-preserving prosthesis (p<0.001). Both groups 21 
experienced similar changes in bone turnover markers and improvement in PROMs scores 22 
over the study period (p>0.05). The adverse event rate was lso similar between groups 23 
(p>0.05). 24 
Conclusions 25 
 3 
This RCT shows that prostheses intended to preserve proximal femoral bone do not 26 
necessarily perform better in this regard than conventional cementless designs. DXA-RFA 27 
is a sensitive tool for detecting spatially-complex patterns of periprosthetic bone 28 
remodeling. 29 
Level of Evidence: 30 
Therapeutic Level 1  31 
 4 
Introduction 32 
Although pooled data from THA case-series and joint registries shows a 25-year 33 
prosthesis survivorship of between 58%-78%1, the burden of periprosthetic femoral fracture 34 
after total hip arthroplasty (THA) continues to increase2. This observation has prompted the 35 
emergence of shorter-stemmed, ‘bone-preserving’ femoral prostheses intended to mitigate 36 
the periprosthetic fracture risk and simplify revision surgery. Those advocating for shorter 37 
stems argue for reduced femoral bone removal at surgery, reduced strain-adaptive 38 
remodeling (stress shielding) within the proximal femur, and tissue-sparing approaches 39 
during femoral canal preparation and prosthesis insertion3, 4.  40 
At prosthesis design, computational modeling techniques such as finite element 41 
analysis (FEA) are commonly used to predict and optimize prosthesis-bone construct 42 
stability and load transfer characteristics5, 6. In order to validate FEA findings in patients, a 43 
clinical measure of bone strain-adaptive remodeling is required, and Dual-energy X-ray 44 
Absorptiometry (DXA) is typically used for this purpose7-9. However, DXA analysis using 45 
the conventional Gruen zone region of interest (ROI) approach has limited ability to resolve 46 
spatially-complex patterns of bone remodeling around prostheses10. To address this, DXA-47 
Region Free Analysis (DXA-RFA) was developed, allowing resolution of bone mineral 48 
density (BMD) at the individual pixel level11-14 and because it does not average the 49 
pixel-level data into ROIs, there is no loss of resolution and interpretation variations 50 
associated with conventional DXA studies15.  51 
The primary aim of this randomized controlled trial (RCT) was to determine 52 
whether periprosthetic bone loss measured by DXA-RFA over 2-years after THA using the 53 
proximally porous-coated and shorter stemmed Tri-Lock “Bone-Preserving Stem” (BPS®) 54 
 5 
femoral prosthesis (DePuy Synthes, Warsaw, USA) is lower than that occurring around the 55 
conventional collarless Corail® prosthesis (DePuy Synthes). We also compared 56 
biochemical markers of bone turnover, patient-reported outcome measures (PROMs) and 57 
adverse events (AEs) between groups. 58 
 59 
Materials and Methods 60 
Between May 2013 and May 2017, 2485 patients underwent THA at The Ottawa Hospital 61 
amongst six surgeons. Initial screening eliminated 1927 patients for the following two 62 
reasons: two surgeons were not participating in the study (n=689); and initial chart 63 
reviewed by the research team met the exclusion criteria (n=1238). A consecutive 64 
group of 558 patients were further interviewed  for eligibility out of which 88 patients 65 
with idiopathic osteoarthritis of the hip were recruited to the trial (Figure 1). The trial was 66 
IRB-approved, registered with clinicaltrials.gov (NCT01558752), and conducted in 67 
accordance with the Declaration of Helsinki. Patients with prior hip surgery, severe femoral 68 
bone deficiency, femoral neck fracture, known secondary causes of arthritis, known 69 
metabolic bone disease and past or present use of drugs known to affect bone metabolism, 70 
and patients anticipated to receive contralateral hip surgery within 1-year, were excluded 71 
from the study. Using computer-generated, varied block randomization with allocation 72 
concealment, patients were randomized during the preoperative outpatient visit. Treatment 73 
allocation was made on a 1:1 basis to receive either the Tri-Lock BPS with a modular 74 
cementless porous-coated acetabular component (Pinnacle®, Depuy Synthes) using a 75 
metal-on-polyethylene bearing surface, or the Corail® prosthesis with a titanium porous-76 
coated monoblock shell (DeltaMotion®, Depuy Synthes) using a ceramic-on-ceramic 77 
 6 
bearing surface. The Tri- Lock “Bone-Preserving Stem” (BPS®) femoral prosthesis 78 
(DePuy Synthes, Warsaw, USA) is a commonly used example of this philosophy. 79 
Manufactured in TiAl6V4 alloy with a stem length of 95 to 119mm, the Tri-Lock 80 
prosthesis has a thin tapered-wedge geometry with a reduced lateral shoulder and 81 
GRIPTION® porous titanium coating in its proximal (metaphyseal) section (pore size 82 
300 microns, volume porosity 80%)  that is designed to closely fit the proximal 83 
femoral metaphysis and promote osseointegration. The prosthesis is inserted with a 84 
bone-cutting broach. The Corail is also a tapered-wedge stem composed of the same 85 
TiAl6V4 alloy, but with a more conventional geometry and is fully hydroxyapatite-86 
coated (HA thickness 155 microns, pore size 250 microns, volume porosity 75%). The 87 
Corail is inserted using a compaction broach. After randomization, two patients 88 
allocated to the Corail group received an alternate implant as the femoral canal was deemed 89 
by the surgeon to be not suitable for the Corail prosthesis and were excluded from further 90 
study. The participant and allied health providers remained blinded to treatment group 91 
allocation until after the final study visit (2-years). 92 
Surgical technique. In all, 46 patients received the Tri-Lock prosthesis and 40 received the 93 
Corail. Each prosthesis was inserted according to its specific manufacturer’s instructions 94 
and design philosophy. Four surgeons performed the procedures, each using their preferred 95 
surgical approach. In the Tri-Lock group 33 were performed using the anterior approach, 6 96 
lateral, 1 posterior, and 6 posterolateral; and for the Corail 26 were anterior, 8 lateral, 1 97 
posterior, and 5 posterolateral (chi-squared = 0.792, p=0.851). Postoperatively, immediate 98 
full weight-bearing was allowed using crutches. Routine postoperative thromboembolic 99 
 7 
prophylaxis consisted of 5 days of 10mg rivaroxaban daily, followed by 25 days of 81mg 100 
aspirin daily. 101 
Outcome measures and monitoring. All DXA scan acquisitions were made using the 102 
same GE Lunar iDXA densitometer (GE Healthcare Lunar, Madison, WI) in ‘orthopaedic’ 103 
scan mode and using a standard acquisition protocol16. Scans were made at post-operative 104 
baseline (within 2-weeks of surgery), and at weeks 26, 52 and 104 postoperatively. 105 
Analysis of the acquired pixel-level bone maps was made using the ‘Encore’ windows-106 
based user interface (GE Healthcare) and implemented in Matlab v9.5 R2018b (Mathworks 107 
Inc, Cambridge, MA). Each image was composed of approximately 10,000 pixels (each 108 
0.60mmx0.60mm in size), and analyzed according to a previously described protocol13. A 109 
post-operative baseline conventional BMD measurement of the contralateral native 110 
hip (without THA) was also made to assess for evidence of pre-existing osteoporosis. 111 
Biochemical markers of bone turnover were measured from morning-fasting serum samples 112 
taken at pre-operative baseline and at weeks 12, 26, 52 and 104. Carboxy-terminal 113 
telopeptide of type I collagen (CTX), a marker of type-I collagen resorption, was measured 114 
by electrochemiluminescent assay (ș-CrossLaps, Elecysy, Roche Diagnostics, 115 
Indianapolis, USA). Intact amino-terminal propeptide of type I procollagen (PINP), a 116 
marker of type-I collagen formation, was also measured using the Elecysy system. 117 
 Plain radiographic assessments using anteroposterior pelvic and lateral radiographs, 118 
were made post-operatively and at weeks 12, 26, 52, and 104. Differences between 119 
preoperative and postoperative global offset, as well as leg length discrepancy, were 120 
measured by an arthroplasty surgeon, following previously described methods7. The canal 121 
flare index was measured as per Boyle et al.17 (stovepipe<3, normal 3-4.7, champagne flute 122 
 8 
>4.7-6.5). Stem alignment was measured and grouped in varus (≥鳥+1°), neutral 123 
(<鳥+1°/>鳥−1°) and valgus position (≤鳥−1°). Characterization of lucencies and bone 124 
resorption was based on the zones described by Gruen with a slight modification for the 125 
short stem18. Non-progressive periprosthetic lucencies of <2mm, outlined by a thin sclerotic 126 
line, were considered as normal8. 127 
PROMs assessments and recording of AEs were made on the same day as the 128 
radiological assessments. PROMs included the modified Harris Hip Score (mHHS)19, the 129 
Western Ontario and McMaster University Osteoarthritis Index (WOMAC)20 score and the 130 
University of California, Los Angeles (UCLA) activity scale 21.  131 
 132 
Statistical analysis. All analyses were made ‘per-protocol’ using two-tailed testing and a 133 
critical p-value of 0.05. Categorical data was analyzed using the chi-squared test. 134 
Continuous data were analyzed parametric and non-parametric tests, as appropriate to each 135 
dataset distribution. Longitudinal continuous data was analyzed by repeated-measures 136 
ANOVA. For DXA-RFA, these analyses were made after correction for multiple testing 137 
by False Discovery Rate (FDR)14, and denoted as q-values (with  q≤0.05 considered 138 
statistically significant). The power calculation was based upon data for cementless femoral 139 
prostheses assuming a between-group difference in Gruen zone 7 of 0.14g/cm2 (10%, 140 
standard deviation 0.23) by conventional DXA analysis, giving a sample size of 43 141 
participants per group for 80% power at the 5% significance level. 142 
 143 
Source of Funding 144 
The project was funded by Johnson & Johnson Medical Products and Synthes 145 
Canada Ltd. (d.b.a. DuPuy Synthes). The funder manufactures all prostheses studied in this 146 
 9 
work, took no part in the design or conduct of the trial, analysis or interpretation of the 147 
results or preparation of the manuscript. 148 
 149 
Results 150 
A total of 47 females and 39 males with a mean age of 59.4±10.6 years old 151 
completed follow-up (98% of subjects randomized) and were included in the analysis. 152 
Patients in the Tri-Lock group (n=46) were of similar age, sex, body mass index (BMI) as 153 
those on the Corail group (n=40, Table 1, p>0.05 all comparisons). BMD of the 154 
contralateral native proximal femur was also similar between groups and within the 155 
normal expected reference ranges (BMD, t- and z-scores p>0.05 all comparisons). 156 
There were more patients in American Society of Anaesthesia (ASA) class III in the Tri-157 
Lock versus the Corail group (p=0.049).  158 
At immediate post-operative baseline, the distribution of periprosthetic BMD was 159 
similar between groups (Figure 2). Subsequent bone loss around both prostheses was  160 
observed in the area of the calcar nd in a cancellous area of the distal greater trochanter 161 
(Figure 3). Bone loss was significantly greater in the Tri-Lock group versus the Corail 162 
over the 2-year study period and observed at all interval timepoints (ANOVA 163 
p<0.0001, Table 2). Small areas of significant bone gain were also observed over the 164 
follow up period that was broadly but sparsely distributed for both prosthesis types 165 
(Figure 3). This gain was initially more apparent in the inferior lesser trochanter in 166 
the Tri-Lock group (p<0.001), but over the full study period was greater in the Corail 167 
group (Table 2 ANOVA p<0.001).   168 
 At pre-operative baseline, serum values for the bone resorption marker CTX and the 169 
bone formation marker PINP were similar (P>0.05 both comparisons, Table 1). Post-170 
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operatively both bone turnover markers underwent a transient increase, peaking at week 26, 171 
before returning to baseline by week 52 (Figure 4). No between-group differences in bone 172 
turnover markers were identified (ANOVA, p>0.05 both comparisons).  173 
At preoperative radiological assessment, the mean canal flare index was 3.92±0.6, 174 
and was similar between groups (p=0.549). On immediate post-operative radiographs, the 175 
prosthesis was positioned in greater varus in the Corail versus the Tri-Lock group (mean 176 
2.07° versus 0.78° p=0.001 Table 3). Other radiographic parameters were similar between 177 
groups. Non-progressive, <2mm lucent lines were detected in zones 1 and 7 of one Tri-178 
Lock stem and in the same zones of three Corail stems. No cases had evidence of femoral 179 
component loosening. 180 
Patients in both treatment groups had similar mHHS, WOMAC and ULCA scores 181 
at pre-operative baseline (p>0.05 all comparisons, Table 4). Both groups experienced 182 
similar improvements in all PROM scores at week 104, with no difference in the change 183 
scores between groups.  There were 8 AEs in the Tri-Lock group and 5 in the Corail group 184 
(p=0.741). This included 3 (7.5%) calcar cracks in the Corail group and 1 (2.17%) in 185 
the Tri-Lock group; 1 (2.5%) deep infection in the Corail group; 1 (2.2%) femoral 186 
nerve palsy in the Tri-Lock group; and 6 episodes of postoperative thigh pain at the 187 
latest follow-up (5 [10.9%] in the Tri-Lock group and 1 [2.5%] in the Corail). One 188 
case (2.2%) in the Tri-Lock group developed aseptic loosening and underwent revision 189 
surgery with a non-modular, distally-fixed, conical stem at week 96.  190 
We used linear regression analysis to explore the relationships between the area of 191 
greatest bone loss within the proximal medial femur and possible predictive factors, 192 
including age, sex, radiographic and PROMs variables. Although a correlation matrix 193 
suggested a relation between prosthesis alignment and BMD change at week 104 (Pearson 194 
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r= 0.386, p<0.001), this was entirely accounted for by prosthesis group. In the final 195 
regression model, only prosthesis group remained a significant predictor of bone loss in the 196 
proximal medial femur (adjusted r2= 0.063, Beta=7.591 (standard error=2.996); p=0.013), 197 
with greater loss for the Tri-Lock prosthesis. 198 
 199 
Discussion 200 
The goal of modern joint arthroplasty is to create a prosthesis-host construct that 201 
provides predictable pain relief and restores function, whilst causing the minimal possible 202 
disruption to the local biological environment18. The emergence of shorter “bone-203 
preserving” femoral prostheses follows that philosophy, but the effect of these prostheses 204 
on the local bone environment in the patient remains unclear22 and is mainly based on 205 
FEA modeling17, 23-26. In this 2-year RCT, both the Tri-Lock BPS and CORAIL designs 206 
resulted in only a modest disturbance of the natural patterns of strain-adaptive remodeling 207 
of the proximal femur, and both performed similarly in terms of plain radiographic 208 
outcomes, PROMs and AE rates. Both designs are tapered wedges made from the 209 
same titanium alloy, but differ in stem length, geometry, extent and type of surface 210 
coating, and fixation philosophy (3-point fixation versus conventional taper). However, 211 
contrary to our anticipated results, we found better bone conservation around the 212 
conventional prosthesis than the proposed bone-preserving one. 213 
In  a post-mortem study, Engh27, demonstrated the effect of prosthesis stiffness on 214 
the local bone environment and whereby short stems would load the proximal femur in 215 
a more physiological way, therefore preventing future stress shielding. Several 216 
authors have studied this looking at a variety of stem designs with mixed results 217 
(Table 5)28-32. However, given the diversity of conventional and short stems available 218 
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in the market and each with different load-sharing philosophies22, our results cannot 219 
be extrapolated to other designs that were not subjected to a similar high-resolution 220 
DXA-RFA analysis. Similarly, canal preparation technique may also affect 221 
periprosthetic bone remodeling. In the non-destructive clinical setting, Hjorth et al 222 
compared compaction versus standard broaching when implanting the same Bi-Metric 223 
stem, and found only minor BMD differences in favor of compaction at 1- and 5-years33. 224 
Their study used conventional DXA analysis that was not able to resolve the implant-225 
bone interface. Using DXA-RFA we resolved events at pixel level at this interface and 226 
found no substantial difference between the implant groups to suggest a meaningful 227 
effect of broaching technique on the initial periprosthetic interface BMD. Further, 228 
given that the post-operative changes in BMD between the groups were not 229 
differentially located at the implant-bone interface, we conclude that the differences in 230 
broaching technique between the groups was not a significant contributor to the 231 
observed BMD outcomes.  232 
Modern imaging approaches, such as computational tomography and magnetic 233 
resonance imaging, also provide cross-sectional detail at high-resolution. However, despite 234 
advances in metal-reduction sequences, challenges due to beam hardening, metal 235 
susceptibility artifacts and other issues remain that limit their application when 236 
studying events at or near the implant-bone interface34-36. DXA-RFA applied here, 237 
apart from not  suffering artifact limitations to the same extent, uses advanced 238 
computer vision algorithms to resolve bone architecture including events at the implant-239 
bone interface15, and allows study of any prosthesis geometry without the resolution and 240 
sampling limitations of ROI-based analysis37, 38. However, as each prosthesis and its 241 
canal preparation technique (i.e. different broach designs) are not separable, we re 242 
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unable to comment directly on the independence of each element on the overall 243 
observed bone remodeling effects. 244 
Our study also has limitations. The inclusion of different bearing surface couple 245 
for each femoral prosthesis may be considered as a potential confounding factor in 246 
respect of axial load transferred to the proximal femur. However, in the design of this 247 
study we did not consider this to be a material issue, based upon previous literature 248 
addressing this question. In 2007, Kim et al reported the results of an RCT in which 249 
50 subjects undergoing simultaneous, bilateral, cementless THA received an alumina-250 
on-alumina bearing in one hip and an alumina-on-polyethylene in the other, finding 251 
no differences in proximal femoral periprosthetic BMD between the bearing couples 252 
over 5 years39.  253 
The 2-year timeframe does not reflect the service life of the prosthesis. However, 254 
this study was constructed to quantitate the effect of each prosthesis philosophy on bone 255 
remodeling over the period when these changes are most dynamic. Our biochemical 256 
marker data confirmed that the major phase of prosthesis-related bone remodeling is 257 
complete within the 2-year timeframe used in this study (return of markers to baseline 258 
bone turnover rates), and are consistent with previous studies of femoral st in-adaptive 259 
bone remodeling after THA40, 41. Our biomarker data did not differentiate the prosthesis 260 
brands. Serum biomarker data reflect bone turnover events throughout the body. Whilst the 261 
observed biomarker changes reflected the surgical event, it is perhaps not surprising that 262 
they were insufficiently sensitive to resolve the subtle differences in local bone remodeling 263 
observed between the prostheses. DXA-RFA, like all DXA analyses, provides a 2-264 
dimensional composite of 3-dimensional events. However, this is a limitation of DXA itself 265 
 14 
rather than the RFA-analysis technology that can also be applied to cross-sectional image 266 
data. 267 
 Although modestly different in their bone remodeling characteristics, this trial 268 
shows that the Corail prosthesis has more favorable bone remodeling characteristics than 269 
the Tri-Lock BPS. However, large-scale clinical data also shows us that design features 270 
which facilitate proximal load transfer and reduce early periprosthetic fracture rates do not 271 
necessarily perform in the same way l ter in the prosthesis’ service life42. Ultimately, long-272 
term periprosthetic fracture and loosening-free prosthesis survival in large clinical series 273 
will determine the clinical significance of more physiological loading of the femur in 274 
regards to a cementless prosthesis design’s overall performance43, 44. 275 
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Legend to figures 431 
 432 
Figure 1. Consort diagram showing patient selection, treatment allocation and analysis 433 
between the prosthesis groups. 434 
 435 
Figure 2. Heatmaps showing baseline pixel-level BMD distribution in each prosthesis 436 
group measured by DXA-RFA.  437 
 438 
Figure 3. Heatmaps showing pixel-level change in BMD over 104 weeks in each 439 
prosthesis group measured by DXA-RFA. Left 3 panels show percentage BMD change 440 
at each timepoint after FDR correction. Right 2 panels show within group areas of 441 
significant change (Q value). Between group analyses for areas of loss and gain are by 442 
repeated measures ANOVA over 104 weeks. 443 
 444 
Figure 4. Graphs showing changes in serum concentrations of A) Carboxy-terminal 445 
telopeptide of type I collagen (CTX), and B) Amino-terminal propeptide of type I 446 
procollagen (PINP) in each prosthesis group over 104 weeks. Analysis is between group by 447 
repeated-measures ANOVA over 104 weeks.  448 
Table 1. Baseline demographic characteristics of completing participants. Values are mean 
± standard deviation. Analyses are between group by †Chi-squared test or ‡t-test. 
 
Variable Tri-Lock Prosthesis 
(n=46) 
Corail prosthesis 
(n=40) 
p-value 
Gender 
   Male 
   Female 
 
22 
24 
 
17 
23 
 
 
0.621† 
Age in years 60.4 ± 10.1 58.6 ± 10.2 0.312‡ 
BMI 27.4 ± 2.9 27.6 ± 2.5 0.859‡ 
ASA class (Count, %) 
I 
II  
III  
IV  
 
1 
28 
17 
0 
 
3 
31 
6 
0 
 
0.049† 
Baseline CTX (ng/ml) 0.425 ± 0.193 0.403 ± 0.186 0.609‡ 
Baseline PINP (ng/ml) 54.47 ± 21.39 55.92 ± 10.82 0.753‡ 
 Contralateral native 
hip (n=36) 
Contralateral native 
hip (n=33) 
 
Total hip BMD (g/cm2) 1.01 ± 0.14 1.01 ± 0.148 0.966‡ 
t-score total hip -0.28 ± 1.07 -0.25 ± 0.99 0.889‡ 
z-score total hip 0.40 ± 1.18 0.39 ± 0.90 0.953‡ 
 
Table 1
Table 2. Pixel-level bone mineral density changes in the Tri-Lock versus Corail Prosthesis 
groups over 104 weeks. Analysis is number of pixels with change/total number of pixels in Tri-
Lock versus Corail group by Repeated Measures ANOVA after False Discovery Rate correction 
at 5%. †Indicates post-hoc p-value at interval timepoints. 
 
Mean ± SD number of pixels/total per femur with significant BMD decrease 
Time Tri-Lock Corail p-value 
26 weeks 927/9460 (9.80%) ± 82 0/11115 (0.00%) ± 0 <0.001† 
52 weeks 661/9460 (6.99%) ± 67 504/11115 (4.53%) ± 76 <0.001† 
104 weeks 1295/9460 (13.69%) ± 73 1072/11115 (9.64%) ± 50 <0.001† 
ANOVA  <0.001 
Mean ± SD number of pixels/total per femur with significant BMD increase 
Time Tri-Lock Corail p-value 
26 weeks 21/9460 (0.22%) ± 6 0/11115 (0.00%) ± 0 <0.001† 
52 weeks 61/9460 (0.64%) ± 7 67/11115 (0.60%) ± 6 0.002† 
104 weeks 122/9460 (1.29%) ± 11 374/11115 (3.36%) ± 40 <0.001† 
ANOVA  <0.001 
Table 2
Table 3. Radiographic outcomes of both prostheses by week 104. Values are mean ± standard 
deviation. Analyses are between groups by t-test. 
 
 
Radiographic variable Tri-Lock prosthesis 
(n=46) 
Corail prosthesis 
(n=40) 
p-value 
Mean global offset 
difference (mm) 
0.02 ± 5.13 
 
-1.57 ± 4.77 
 
0.072 
 
Mean leg length 
discrepancy (mm) 
-0.09 ± 1.82 
 
0.73 ± 1.86 
 
0.028 
 
Mean stem alignment angle 
(degrees, varus +, valgus -) 
0.78 ± 1.52 
 
2.07 ± 2.11 
 
< 0.001 
 
Mean linear bone 
resorption at calcar (mm) 
0.78 ± 0.94 
 
0.65 ± 0.92 
 
0.451 
 
Table 3
Table 4. Patient-reported outcome measures in the Tri-Lock versus Corail groups at pre-
operative baseline and at week 104. Values are mean ± standard deviation. Analysis is: † within 
group between baseline and week 104 by paired t-test, and †† between group improvement in 
PROM score by independent t-test 
PROMs (mean ± SD) Tri-Lock Prosthesis 
(n= 46) 
Corail prosthesis 
(n= 40) 
p-
value 
††p-value 
change scores 
between groups 
Pre Harris Hip Score - 
Pain 
17.5 ± 7.19 19.2 ± 7.12 0.231 
 
0.728 
Post Harris Hip Score - 
Pain 
35.6 ± 8.43 36.9 ± 8.96 0.342 
†p-value <0.001 <0.001   
Pre Harris Hip Score - 
Function 
27.7 ± 7.64 29.9 ± 6.83 0.167 
 
0.132 
Post Harris Hip Score - 
Function 
42.0 ± 5.77 42.6 ± 7.40 0.275 
†p-value <0.001 <0.001   
Pre WOMAC - Pain 47.3 ± 17.7 55.0 ± 14.9 0.054 0.362 
Post WOMAC - Pain 87.2 ± 16.2 87.8 ± 16.8 0.661 
†p-value <0.001 <0.001   
Pre WOMAC - Stiffness 43.8 ± 20.7 
 
45.0 ± 19.2 
 
0.518 0.890 
Post WOMAC - Stiffness 78.5 ± 21.5 82.6 ± 22.0 0.284 
†p-value <0.001 <0.001   
Pre WOMAC - Function 47.0 ± 17.1 58.4 ± 17.7 0.007 0.876 
Post WOMAC - 
Function 
87.2 ± 14.4 90.6 ± 15.8 0.150 
†p-value <0.001 <0.001   
Pre UCLA 4.80 ± 1.78 5.23 ± 2.07 0.491 0.329 
Post UCLA 6.26 ± 1.89 6.24 ± 2.16 0.654 
Table 4
 
†p-value <0.001 <0.001   
Table 5: Previous randomized controlled trials (2015-onwards) reporting on bone mineral density results of a variety of stem 
designs. 
 
Study No. of hips (n) Comparison 
groups 
Mean Follow-up Results Limitations 
Schilcher et al 
(2017)28 
60 Standard 
cementless 
femoral stem 
(Taperloc) vs. a 
35-mm shorter 
version 
(Microplasty). 
2-year Greater bone loss around the 
shorter stem, although this was 
not statistically significant. 
Underpowered to 
detect a 
significant 
difference in 
BMD between the 
prostheses. 
Meyer et al 
(2019)29 
140 Cementless bone 
preserving stem 
(Fitmore) vs. 
cementless 
straight stem 
(CLS Spotorno). 
5-year The bone-preserving Fitmore 
stem exhibited less proximal 
femoral bone loss that the CLS 
Spotorno conventional stem. 
Different stem 
length of the 2 
implants used 
with a 
modification to 
Gruen zones for 
better 
comparability. 
Salemyr et al 
(2015)30 
51 Ultra-short stem 
(Proxima) vs. 
conventional 
tapered stem (Bi-
metric). 
2-year The conventional stem had 
greater bone loss (mainly in 
Gruen zones 1 and 7). 
Lack of patient 
blinding. Possibly 
underpowered. 
Freitag et al 
(2016)31 
144 Cementless bone 
preserving stem 
(Fitmore) vs. 
cementless 
straight stem 
(CLS Spotorno). 
1-year Although both designs had 
implant-specific 
stress-shielding, the Fitmore 
stem had less proximal femoral 
bone loss that the CLS Spotorno 
stem (at ROI 6). 
Short follow-up. 
Kim et al 
(2016)32 
400 Ultrashort 
anatomic 
12-year BMD was greater in the 
ultrashort stem group than in 
Difficulty at 
evaluating 
Table 5
cementless stem 
(Proxima) vs. 
conventional 
anatomic 
cementless stem 
(Profile) 
the conventional stem group 
(mostly in zones 1 and 7). 
longitudinal BMD 
changes using 
conventional 
DEXA of 2 
different stem 
designs (e.g. 
slight 
changes in 
femoral rotation 
can affect 
precision of the 
measurement). 
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